Compare Citius Pharmaceuticals Inc (CTXR) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while YieldMax Universe Fund of Option Income ETFs trades at $7.61 (market cap $364M). The key difference: YieldMax Universe Fund of Option Income ETFs is far larger — about 26.7× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 1,181,378). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| CTXR | YMAX | |
|---|---|---|
Market Cap | $13.62M | $364M |
Volume | 132,438 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $12.70 |
52-Week Low | $0.48 | $7.27 |
Typical Hold Time | 17 Days | 56 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
YMAX trades at $7.48, down 0.66% with a bearish technical outlook. The ETF shows persistent NAV erosion despite high distributions, with the share price declining 22.7% year-to-date. Recent portfolio adjustments aim to address performance concerns, but structural costs and distribution sustainability remain key investor focus areas.
The fund faces significant headwinds from its fund-of-funds structure stacking costs, with a 1.33% base fee plus underlying ETF expenses. While offering 40%+ annualized yields, the distribution policy appears unsustainable given NAV declines. Investors face principal erosion risks despite high income payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
